Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Opportunities to Optimize Cancer Policies Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Apr
30
Today In Oncology
AI Driven Analysis of Digital Pathology Images May Improve Sarcoma Subtyping Among Pediatric Patients
Sex Disparities Identified in Fatigue and Depression for Cancer Survivors
AI-Driven Model For Identifying Cancer Cachexia
Topical BRAF Inhibitor Under Study for Managing Acneiform Rash
Molecularly Selected, Tumor-Agnostic Phase II Trial Focuses on Combination Therapy
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo